Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
2.
Transpl Infect Dis ; 19(2)2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28099778

RESUMO

Non-Candida opportunistic yeasts are emerging causes of bloodstream infection (BSI) in immunocompromised hosts. However, their clinical presentation, management, and outcomes in stem cell transplant (SCT) recipients are not well described. We report the first case to our knowledge of Pseudozyma BSI in a SCT recipient. He had evidence of cutaneous involvement, which has not been previously described in the literature. He became infected while neutropenic and receiving empiric micafungin, which is notable because Pseudozyma is reported to be resistant to echinocandins. He was successfully treated with the sequential use of liposomal amphotericin B and voriconazole. A review of the literature revealed nine reported instances of Pseudozyma fungemia. We performed a retrospective review of 3557 SCT recipients at our institution from January 2000 to June 2015 and identified four additional cases of non-Candida yeast BSIs. These include two with Cryptococcus, one with Trichosporon, and one with Saccharomyces. Pseudozyma and other non-Candida yeasts are emerging pathogens that can cause severe and disseminated infections in SCT recipients and other immunocompromised hosts. Clinicians should have a high degree of suspicion for echinocandin-resistant yeasts, if patients develop breakthrough yeast BSIs while receiving echinocandin therapy.


Assuntos
Antifúngicos/uso terapêutico , Dermatomicoses/microbiologia , Exantema/microbiologia , Fungemia/microbiologia , Infecções Oportunistas/microbiologia , Ustilaginales/patogenicidade , Leveduras/patogenicidade , Adulto , Anfotericina B/administração & dosagem , Anfotericina B/uso terapêutico , Antifúngicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Biópsia , Cryptococcus/isolamento & purificação , Cryptococcus/patogenicidade , Citarabina/uso terapêutico , Dermatomicoses/sangue , Dermatomicoses/tratamento farmacológico , Dermatomicoses/patologia , Equinocandinas/administração & dosagem , Equinocandinas/uso terapêutico , Exantema/sangue , Exantema/tratamento farmacológico , Exantema/patologia , Febre/microbiologia , Fungemia/tratamento farmacológico , Fator Estimulador de Colônias de Granulócitos/uso terapêutico , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Idarubicina/uso terapêutico , Hospedeiro Imunocomprometido , Leucemia Mielogênica Crônica BCR-ABL Positiva/terapia , Lipopeptídeos/administração & dosagem , Lipopeptídeos/uso terapêutico , Masculino , Micafungina , Infecções Oportunistas/sangue , Infecções Oportunistas/tratamento farmacológico , Estudos Retrospectivos , Saccharomyces/isolamento & purificação , Saccharomyces/patogenicidade , Terapia de Salvação/métodos , Trichosporon/isolamento & purificação , Trichosporon/patogenicidade , Ustilaginales/isolamento & purificação , Vidarabina/análogos & derivados , Vidarabina/uso terapêutico , Voriconazol/administração & dosagem , Voriconazol/uso terapêutico , Leveduras/isolamento & purificação
3.
Anaerobe ; 34: 84-5, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25881498

RESUMO

We report two cases of bacteremia with Actinobaculum schaalii, a rarely reported, anaerobic, Gram-positive bacterium. The first case was a patient with renal cancer who developed pyelonephritis after cryoablation, and the second was a patient who developed sepsis after a urogenital procedure. Bacteremia resolved after administration of empiric antibiotic therapy.


Assuntos
Actinomycetaceae/isolamento & purificação , Infecções por Actinomycetales/diagnóstico , Infecções por Actinomycetales/patologia , Bacteriemia/diagnóstico , Bacteriemia/patologia , Actinomycetaceae/classificação , Infecções por Actinomycetales/tratamento farmacológico , Infecções por Actinomycetales/microbiologia , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/microbiologia , Bactérias Anaeróbias/classificação , Bactérias Anaeróbias/isolamento & purificação , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
4.
Artigo em Inglês | MEDLINE | ID: mdl-38156230

RESUMO

Chat Generative Pre-trained Transformer (ChatGPT), the flagship generative artificial intelligence (AI) chatbot by OpenAI, is transforming many things in medicine, from healthcare and research to medical education. It is anticipated to integrate in many aspects of the medical industry, and we should brace for this inevitability and use it to our advantage. Here are proposed ways you can use ChatGPT in medicine with some specific use cases in antimicrobial stewardship and hospital epidemiology.

5.
Gastroenterol Clin North Am ; 50(2): 415-430, 2021 06.
Artigo em Inglês | MEDLINE | ID: mdl-34024449

RESUMO

Infectious gastroenteritis is common after transplantation and can lead to increased morbidity and mortality. A wide range of organisms can lead to gastroenteritis in this patient population. Clostridioides difficile, cytomegalovirus, and norovirus are the most common pathogens. Newer diagnostic methods, especially multiplex polymerase chain reaction, have increased the diagnostic yield of infectious etiologies. In this review, we describe the epidemiology and risk factors for common infectious pathogens leading to gastroenteritis.


Assuntos
Gastroenterite , Transplante de Células-Tronco Hematopoéticas , Norovirus , Transplante de Órgãos , Diarreia , Gastroenterite/diagnóstico , Gastroenterite/epidemiologia , Gastroenterite/etiologia , Humanos , Norovirus/genética , Transplante de Órgãos/efeitos adversos
6.
J Infect ; 74(2): 179-186, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27777118

RESUMO

BACKGROUND: Staphylococcus lugdunensis is a coagulase-negative staphylococcus with similar virulence characteristics as Staphylococcus aureus. Whether S. lugdunensis causes infective endocarditis (IE) in a similar proportion of cases as S. aureus (reported to be 12.6% in a definitive multicenter prospective study) is unclear. METHODS: We conducted a retrospective cohort study of adult patients with at least one blood culture positive for S. lugdunensis at our institution from January 2006 to December 2014. We examined microbiology data, ascertained disease severity and determined the proportion of patients with definite or possible IE based on the 2000 Modified Duke Criteria. Because coagulase-negative staphylococci were routinely identified to the species level at our institution from 2012 onwards, we determined the proportion of patients with definite or possible IE before and after implementation of routine speciation. We also compared our results with reported proportions of IE among patients with S. lugdunensis bacteremia (SLB) in other institutions by conducting a systematic review of the scientific literature. Nonparametric bootstrapping methods were performed to determine 95% confidence intervals (CI) for proportions of IE in patients with SLB. RESULTS: Seventy-four patients with SLB were identified, of whom 64% (47/74) had sepsis by SIRS criteria, and 18% (13/74) had severe illness by Pittsburgh bacteremia score (PBS). Kaplan-Meier survival analysis showed that one-year survival among patients with severe illness was worse than patients with non-severe illness (p = 0.02). Fifteen percent (11/74) of patients had definite or possible IE (95% CI 6.8-23.0%). The proportion of SLB patients with definite or possible IE was 15.8% (6/38, 95% CI 5.3-28.9%) prior to routine speciation and 13.9% (5/36, 95% CI 2.8-27.8%) after routine speciation (p = 0.71). Among patients with at least two positive blood cultures for S. lugdunensis, 25% (10/40, 95% CI 12.5-40.0%) had IE. Systematic review of the literature yielded eight relevant retrospective studies. Of studies that included patients with one or more positive blood cultures for S. lugdunensis, the proportion of IE ranged from 6.3% to 27.0%. CONCLUSION: The proportion of definite or possible IE among patients with SLB is similar to the proportion of IE among patients with S. aureus bacteremia. The proportions of IE among patients with SLB at other institutions fall within the 95% CI yielded by bootstrapping. Our findings suggest that growth of S. lugdunensis in two separate blood cultures should prompt consideration of workup for IE.


Assuntos
Bacteriemia/microbiologia , Endocardite Bacteriana/epidemiologia , Endocardite Bacteriana/microbiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus lugdunensis/isolamento & purificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Bacteriemia/mortalidade , Estudos de Coortes , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/mortalidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/mortalidade , Staphylococcus lugdunensis/patogenicidade , Estados Unidos/epidemiologia , Adulto Jovem
7.
Transl Res ; 183: 41-56, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28068521

RESUMO

Antiretroviral therapy has revolutionized the care of people with human immunodeficiency virus (HIV) by reducing morbidity and mortality from acquired immunodeficiency syndrome-related conditions. Despite longer life expectancy, however, HIV-infected individuals continue to have a higher risk of death compared with the general population. This has been attributed to the increasing incidence of noncommunicable diseases, in particular, atherosclerotic cardiovascular diseases. This is driven, in part, by the emergence of metabolic disorders, particularly dyslipidemia, insulin resistance, and lipodystrophy, in those on antiretroviral therapy. The pathogenesis of these metabolic derangements is complex and multifactorial, and could be a consequence of an interplay between traditional age-related risk factors, HIV infection, antiretroviral therapy effects, and the inflammatory state and immune activation in this population. Understanding the contributions of each of these factors could not just impact the current management of these individuals and help mitigate the risk for premature cardiovascular disease, but also shape the future direction of research in HIV.


Assuntos
Dislipidemias/etiologia , Infecções por HIV/complicações , Resistência à Insulina/fisiologia , Fármacos Anti-HIV/efeitos adversos , Fármacos Anti-HIV/classificação , Fármacos Anti-HIV/farmacologia , Dislipidemias/prevenção & controle , Infecções por HIV/epidemiologia , Infecções por HIV/imunologia , Infecções por HIV/virologia , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA